Pharmafile Logo
Pharmafocus logo
Advanced Search

moventig

Showing 3 posts of 3 posts found.

AstraZeneca licenses European rights to constipation drug for $70m

March 1, 2016
Manufacturing and Production, Sales and Marketing AstraZeneca, EU, Japan, Luke Miles, ProStrakan Group, constipation drug, moventig

AstraZeneca said on Tuesday it has agreed to licence rights to its constipation drug Moventig to Japan’s ProStrakan Group for …

News
astrazeneca_plaque

AstraZeneca’s Moventig now available through NHS

October 9, 2015
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, moventig

AstraZeneca has announced that Moventig (naloxegol) has been made available for adult patients with opioid-induced constipation (OIC) in England and …

News
AZ image

AstraZeneca constipation drug gets EU nod

December 9, 2014
Sales and Marketing AstraZeneca, KODIAC, NKTR-118, PAMORA, moventig, naloxegol

AstraZeneca’s opioid-induced constipation drug Moventig has been approved by the European Commission. The first once-daily PAMORA tablet to be given …

News

Latest content

FDA approves Amgen’s Imdelltra for extensive-stage small cell lung cancer

May 17, 2024

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

May 17, 2024

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024